Early Administration of Carvedilol Protected against Doxorubicin-Induced Cardiomyopathy
Authors:
- Yung-Lung ChenYCYung-Lung Chen
- Sheng-Ying ChungSCSheng-Ying Chung
- Han-Tan ChaiHCHan-Tan Chai
- Chih-Hung ChenChih-Hung Chen
- Chu-Feng LiuCLChu-Feng Liu
- Yi-Ling ChenYCYi-Ling Chen
- Tien-Hung HuangTHTien-Hung Huang
- Yen-Yi ZhenYZYen-Yi Zhen
- Pei-Hsun SungPei-Hsun Sung
- Cheuk-Kwan SunCheuk-Kwan Sun
- Sarah ChuaSCSarah Chua
- Hung-I LuHLHung-I Lu
- 1 December 2015
- journal article
- research article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 355 (3) , 516-527
Abstract
This study tested for the benefits of early administration of carvedilol as protection against doxorubicin (DOX)-induced cardiomyopathy. Thirty male, adult B6 mice were categorized into group 1 (untreated control), group 2 [DOX treatment (15 mg/every other day for 2 weeks, i.p.], and group 3 [carvedilol (15 mg/kg/d, from day 7 after DOX treatment for 28 days)], and euthanized by day 35 after DOX treatment. By day 35, the left ventricular ejection fraction (LVEF) was significantly lower in group 2 than in groups 1 and 3, and significantly lower in group 3 than in group 1, whereas the left ventricular (LV) end-diastolic and LV end-systolic dimensions showed an opposite pattern to the LVEF among the three groups. The protein expressions of fibrotic (Smad3, TGF-β), apoptotic (BAX, cleaved caspase 3, PARP), DNA damage (γ-H2AX), oxidative stress (oxidized protein), mitochondrial damage (cytosolic cytochrome-C), heart failure (brain natriuretic peptide), and hypertrophic (β-MHC) biomarkers of the LV myocardium showed an opposite pattern to the LVEF among the three groups. The protein expressions of antifibrotic (BMP-2, Smad1/5), α-MHC, and phosphorylated-Akt showed an identical pattern to the LVEF among the three groups. The microscopic findings of fibrotic and collagen-deposition areas and the numbers of γ-H2AX+ and 53BP1+ cells in the LV myocardium exhibited an opposite pattern, whereas the numbers of endothelial cell (CD31+, vWF+) markers showed an identical pattern to the LVEF among the three groups. Cardiac stem cell markers (C-kit+ and Sca-1+ cells) were significantly and progressively increased from group 1 to group 3. Additionally, the in vitro study showed carvedilol treatment significantly inhibited DOX-induced cardiomyoblast DNA (CD90/XRCC1+, CD90/53BP1+, and r-H2AX+ cells) damage. Early carvedilol therapy protected against DOX-induced DNA damage and cardiomyopathy.Keywords
This publication has 35 references indexed in Scilit:
- Heart angiotensin II-induced cardiomyocyte hypertrophy suppresses coronary angiogenesis and progresses diabetic cardiomyopathyAmerican Journal of Physiology-Heart and Circulatory Physiology, 2012
- Autologous bone marrow cell implantation attenuates left ventricular remodeling and improves heart function in porcine myocardial infarction: An echocardiographic, six-month angiographic, and molecular–cellular studyInternational Journal of Cardiology, 2011
- Carvedilol-Afforded Protection against Daunorubicin-Induced Cardiomyopathic Rats In Vivo: Effects on Cardiac Fibrosis and HypertrophyISRN Pharmacology, 2011
- Protective effect of carvedilol on daunorubicin-induced cardiotoxicity and nephrotoxicity in ratsToxicology, 2010
- Attenuation of Doxorubicin-Induced Cardiomyopathy by Endothelin-Converting Enzyme-1 Ablation Through Prevention of Mitochondrial Biogenesis ImpairmentHypertension, 2010
- Vascular dysfunction in idiopathic dilated cardiomyopathyNature Reviews Cardiology, 2009
- Impact of Hyperglycemic Control on Left Ventricular Myocardium A Molecular and Cellular Basic Study in a Diabetic Rat ModelInternational Heart Journal, 2009
- Protective Effects of Carvedilol Against Anthracycline-Induced CardiomyopathyJACC, 2006
- Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart FailureCirculation, 2002
- Doxorubicin-induced calcium release from cardiac sarcoplasmic reticulum vesiclesJournal of Molecular and Cellular Cardiology, 1989